The Corticotropin Releasing Factor Receptor 1 pipeline drugs market research report outlays comprehensive information on the Corticotropin Releasing Factor Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Corticotropin Releasing Factor Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Hormonal Disorders, Women’s Health, and Gastrointestinal which include the indications Central Nervous System, Alzheimer’s Disease, Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Endometriosis, Polycystic Ovarian Syndrome, Irritable Bowel Syndrome, and Gastroparesis. It also reviews key players involved in Corticotropin Releasing Factor Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Corticotropin Releasing Factor Receptor 1 pipeline targets constitutes close to eight molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical, and Discovery stages are 1, 1, 3, and 2 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Corticotropin Releasing Factor Receptor 1 overview
Corticotropin releasing factor receptor 1 (CRHR1) is a G-protein coupled receptor for CRH (corticotropin-releasing factor) and UCN (urocortin) and has high affinity for CRH and UCN. CRHR1 promotes the activation of adenylate cyclase, leading to increased intracellular cAMP levels and playing a role in the response to anxiogenic stimuli. It is required for normal embryonic development of the adrenal gland and for normal hormonal responses to stress.
For a complete picture of Corticotropin Releasing Factor Receptor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
